Literature DB >> 22079265

Protective immunity against mouse upper genital tract pathology correlates with high IFNγ but low IL-17 T cell and anti-secretion protein antibody responses induced by replicating chlamydial organisms in the airway.

Chunxue Lu1, Hao Zeng, Zhihong Li, Lei Lei, I-Tien Yeh, Yimou Wu, Guangming Zhong.   

Abstract

To search for optimal immunization conditions for inducing protective immunity against upper genital tract pathologies caused by chlamydial intravaginal infection, we compared protection efficacy in mice immunized intranasally or intramuscularly with live or inactivated Chlamydia muridarum organisms. Mice immunized intranasally with live organisms developed strong protection against both vaginal shedding of infectious organisms and upper genital tract pathologies. The protection correlated with a robust antigen-specific T cell response with high IFNγ but low IL-17. Although a significant level of IL-5 was also detected, these mice maintained an overall Th1-dorminant immunity following immunization and challenge infection. On the contrary, mice immunized intranasally with inactivated organisms or intramuscularly with live or inactivated organisms produced high levels of IL-17 and still developed significant upper genital tract pathologies. High titers of antibodies against chlamydial secretion antigens were detected only in mice immunized intranasally with live organisms but not mice in other groups, suggesting that the intranasally inoculated live organisms were able to undergo replication and immune responses to the chlamydial secretion proteins may contribute to protective immunity. These observations have provided important information on how to develop subunit vaccines for inducing protective immunity against urogenital infection with Chlamydia trachomatis organisms.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22079265      PMCID: PMC3246108          DOI: 10.1016/j.vaccine.2011.10.059

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  77 in total

1.  PREVENTION OF TRACHOMA WITH VACCINE.

Authors:  J T GRAYSTON; S P WANG; R L WOOLRIDGE; E R ALEXANDER
Journal:  Arch Environ Health       Date:  1964-04

2.  Histopathologic changes related to fibrotic oviduct occlusion after genital tract infection of mice with Chlamydia muridarum.

Authors:  Anita A Shah; Justin H Schripsema; Mohammad T Imtiaz; Ira M Sigar; John Kasimos; Peter G Matos; Sandra Inouye; Kyle H Ramsey
Journal:  Sex Transm Dis       Date:  2005-01       Impact factor: 2.830

3.  The chlamydial plasmid-encoded protein pgp3 is secreted into the cytosol of Chlamydia-infected cells.

Authors:  Zhongyu Li; Ding Chen; Youmin Zhong; Shiping Wang; Guangming Zhong
Journal:  Infect Immun       Date:  2008-05-12       Impact factor: 3.441

Review 4.  Chlamydia vaccine candidates and tools for chlamydial antigen discovery.

Authors:  Daniel D Rockey; Jie Wang; Lei Lei; Guangming Zhong
Journal:  Expert Rev Vaccines       Date:  2009-10       Impact factor: 5.217

5.  CD8+ T cells recognize an inclusion membrane-associated protein from the vacuolar pathogen Chlamydia trachomatis.

Authors:  S P Fling; R A Sutherland; L N Steele; B Hess; S E D'Orazio; J Maisonneuve; M F Lampe; P Probst; M N Starnbach
Journal:  Proc Natl Acad Sci U S A       Date:  2001-01-30       Impact factor: 11.205

6.  Sexually transmitted diseases and tubal pregnancy.

Authors:  K J Sherman; J R Daling; A Stergachis; N S Weiss; H M Foy; S P Wang; J T Grayston
Journal:  Sex Transm Dis       Date:  1990 Jul-Sep       Impact factor: 2.830

7.  Clearance of Chlamydia trachomatis from the murine genital mucosa does not require perforin-mediated cytolysis or Fas-mediated apoptosis.

Authors:  L L Perry; K Feilzer; S Hughes; H D Caldwell
Journal:  Infect Immun       Date:  1999-03       Impact factor: 3.441

8.  Immunogenicity evaluation of a lipidic amino acid-based synthetic peptide vaccine for Chlamydia trachomatis.

Authors:  G Zhong; I Toth; R Reid; R C Brunham
Journal:  J Immunol       Date:  1993-10-01       Impact factor: 5.422

9.  Intracellular interleukin-1alpha mediates interleukin-8 production induced by Chlamydia trachomatis infection via a mechanism independent of type I interleukin-1 receptor.

Authors:  Wen Cheng; Pooja Shivshankar; Youmin Zhong; Ding Chen; Zhongyu Li; Guangming Zhong
Journal:  Infect Immun       Date:  2007-12-17       Impact factor: 3.441

10.  Intranasal administration of chlamydial outer protein N (CopN) induces protection against pulmonary Chlamydia pneumoniae infection in a mouse model.

Authors:  A Tammiruusu; T Penttilä; R Lahesmaa; M Sarvas; M Puolakkainen; J M Vuola
Journal:  Vaccine       Date:  2006-08-11       Impact factor: 3.641

View more
  25 in total

1.  Parenteral vaccination protects against transcervical infection with Chlamydia trachomatis and generate tissue-resident T cells post-challenge.

Authors:  Nina Dieu Nhien Tran Nguyen; Anja W Olsen; Emma Lorenzen; Peter Andersen; Malene Hvid; Frank Follmann; Jes Dietrich
Journal:  NPJ Vaccines       Date:  2020-01-23       Impact factor: 7.344

2.  Protective immunity against Chlamydia trachomatis can engage both CD4+ and CD8+ T cells and bridge the respiratory and genital mucosae.

Authors:  Catarina V Nogueira; Xuqing Zhang; Nicholas Giovannone; Erica L Sennott; Michael N Starnbach
Journal:  J Immunol       Date:  2015-01-30       Impact factor: 5.422

3.  Chlamydia trachomatis outer membrane complex protein B (OmcB) is processed by the protease CPAF.

Authors:  Shuping Hou; Lei Lei; Zhangsheng Yang; Manli Qi; Quanzhong Liu; Guangming Zhong
Journal:  J Bacteriol       Date:  2012-12-07       Impact factor: 3.490

4.  Chlamydia muridarum induction of glandular duct dilation in mice.

Authors:  Xin Sun; Zhangsheng Yang; Hongbo Zhang; Jin Dai; Jianlin Chen; Lingli Tang; Sheena Rippentrop; Min Xue; Guangming Zhong; Ganqiu Wu
Journal:  Infect Immun       Date:  2015-03-30       Impact factor: 3.441

5.  Divergent outcomes following transcytosis of IgG targeting intracellular and extracellular chlamydial antigens.

Authors:  Charles W Armitage; Connor P O'Meara; Marina C G Harvie; Peter Timms; Richard S Blumberg; Kenneth W Beagley
Journal:  Immunol Cell Biol       Date:  2014-01-21       Impact factor: 5.126

6.  Induction of protective immunity against Chlamydia muridarum intravaginal infection with the chlamydial immunodominant antigen macrophage infectivity potentiator.

Authors:  Chunxue Lu; Bo Peng; Zhihong Li; Lei Lei; Zhongyu Li; Lili Chen; Qingzhi He; Guangming Zhong; Yimou Wu
Journal:  Microbes Infect       Date:  2013-02-14       Impact factor: 2.700

7.  Lack of long-lasting hydrosalpinx in A/J mice correlates with rapid but transient chlamydial ascension and neutrophil recruitment in the oviduct following intravaginal inoculation with Chlamydia muridarum.

Authors:  Hongbo Zhang; Zhou Zhou; Jianlin Chen; Ganqiu Wu; Zhangsheng Yang; Zhiguang Zhou; Joel Baseman; Jin Zhang; Robert Lee Reddick; Guangming Zhong
Journal:  Infect Immun       Date:  2014-04-07       Impact factor: 3.441

8.  Signaling via tumor necrosis factor receptor 1 but not Toll-like receptor 2 contributes significantly to hydrosalpinx development following Chlamydia muridarum infection.

Authors:  Xiaohua Dong; Yuanjun Liu; Xiaotong Chang; Lei Lei; Guangming Zhong
Journal:  Infect Immun       Date:  2014-02-18       Impact factor: 3.441

9.  Suppression of Chlamydial Pathogenicity by Nonspecific CD8+ T Lymphocytes.

Authors:  Lingxiang Xie; Conghui He; Jianlin Chen; Lingli Tang; Zhiguang Zhou; Guangming Zhong
Journal:  Infect Immun       Date:  2020-09-18       Impact factor: 3.441

10.  Reduced live organism recovery and lack of hydrosalpinx in mice infected with plasmid-free Chlamydia muridarum.

Authors:  Lei Lei; Jianlin Chen; Shuping Hou; Yiling Ding; Zhangsheng Yang; Hao Zeng; Joel Baseman; Guangming Zhong
Journal:  Infect Immun       Date:  2013-12-16       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.